+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Role of Statin Therapy in Primary Prevention of Cardiovascular Disease in Elderly Patients



Role of Statin Therapy in Primary Prevention of Cardiovascular Disease in Elderly Patients



Current Atherosclerosis Reports 21(8): 28



Hypercholesterolemia and statin treatment are nowadays common among people older than 75 years, but clinical heterogeneity in this increasing age group is wide, and treatment decisions may differ from those in younger patients. Aim is to discuss the presentation, modifying factors, and treatment decisions of hypercholesterolemia (usually with statins) in older persons and focusing on primary prevention. There are no randomized controlled trials in persons older than 80 years at baseline. Randomized controlled trial findings in younger patients and 75+ subgroups and in observational studies support treatment in secondary prevention of atherosclerotic cardiovascular disease (ASCVD), but trial evidence in primary prevention is less clear. Available data do not imply specific harms in older patients, and, therefore, also, judicious primary prevention is possible. However, persons older than 75 years are biologically a very heterogeneous group with frequent frailty, comorbid conditions, and multiple concomitant drugs. All these, as well as personal preferences, must be taken into account in treatment decisions. Statin treatment is only one way to prevent ASCVD in older people. Treatment of hypercholesterolemia should be started far before 75-80 years, and there is no need to discontinue statin treatment due to chronological age alone. After 75 years, treatment should be started in patients with ASCVD and judiciously in primary prevention. Like all prevention, statin treatment should be discontinued when palliative treatment is started. Ongoing and planned trials in 70+ individuals will give more information about primary prevention in older persons.

(PDF emailed within 0-6 h: $19.90)

Accession: 066804074

Download citation: RISBibTeXText

PMID: 31111235

DOI: 10.1007/s11883-019-0793-7


Related references

Statin therapy for primary prevention of cardiovascular disease. JAMA 310(22): 2451-2452, 2013

Long-term Cost-effectiveness of Statin Treatment for Primary Prevention of Cardiovascular Disease in the Elderly. Cardiovascular Drugs and Therapy 29(2): 187-197, 2016

Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia. American Journal of Medicine 114(6): 485-494, April 15, 2003

Cardiovascular Genetic Risk Testing for Targeting Statin Therapy in the Primary Prevention of Atherosclerotic Cardiovascular Disease: A Cost-Effectiveness Analysis. Circulation. Cardiovascular Quality and Outcomes 11(4): E004171, 2018

Combination niacin and statin therapy in primary and secondary prevention of cardiovascular disease. Clinical Cardiology 28(7): 317-320, 2005

Predictors of residual cardiovascular risk in patients on statin therapy for primary prevention. Cardiology 119(4): 187-190, 2012

Statin for the primary prevention of cardiovascular disease in patients with diabetes mellitus. Diabetes and Metabolism Journal 38(1): 32-34, 2014

The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease. Therapeutic Advances in Cardiovascular Disease 3(4): 309-315, 2009

Comparison of 3 risk estimators to guide initiation of statin therapy for primary prevention of cardiovascular disease. Journal of Clinical Lipidology 11(6): 1441-1447, 2017

Individualized Statin Benefit for Determining Statin Eligibility in the Primary Prevention of Cardiovascular Disease. Circulation 133(16): 1574-1581, 2016

Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease. JAMA 314(2): 142-150, 2015

Initiation rates of statin therapy for the primary prevention of cardiovascular disease: an assessment of differences between countries of the UK and between regions within England. Bmj Open 5(3): E007207, 2015

Benefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians - a population with the highest risk of premature coronary artery disease & diabetes. Indian Journal of Medical Research 138(4): 461-491, 2015

Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions. Clinical Therapeutics 31(12): 2919-30; Discussion 2916-8, 2010

Personalized absolute benefit of statin treatment for primary or secondary prevention of vascular disease in individual elderly patients. Clinical Research in Cardiology 106(1): 58-68, 2016